Hydroxychloroquine and colchicine are anti-NLRP3 inflammasome agents and have been tested in clinical trials against COVID-19; however, the completion point has not been reached (Alam et al. 2021; Lopes et al. 2021; Bignardi et al. 2021). Here, NLRP3 is linked to COVID-19.